Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 73   

Articles published

BMY 60.61 -0.21 (-0.35%)
price chart
TEXT-S&P revises Bristol-Myers Squibb short-term rating to 'A-1+'
Overview -- Standard & Poor's Ratings Services has revised its criteria regarding the linkage of issuers' long-term and short-term ratings as they relate to liquidity.
PETA brings animal care proposal, protest to Bristol-Myers Squibb after monkey ...
Bristol-Myers Squibb shareholders overwhelmingly rejected a proposal at their annual meeting yesterday in Plainsboro from an animal rights' group calling for the company to outline its animal care policies. At the meeting, PETA research associate ...
U.S. FDA Approves Bristol-Myers Squibb Devens Biologics Manufacturing Facility ...
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved the company's biologics manufacturing facility in Devens, Massachusetts for commercial ...
Bristol-Myers Squibb forms International Immuno-Oncology Network
Bristol-Myers Squibb Company (NYSE: BMY) today announced the formation of the International Immuno-Oncology Network (II-ON), a global collaboration between industry and academia that aims to further the scientific understanding of immuno-oncology.
Financial Astrology: The Key to Future Investing
He illustrated Amylin (NASDAQ: AMLN), a company that I had recently included as a trade recommendation for my subscribers. We had a recommended long position in Astrology Traders just prior to the Bristol Myers Squibb (NYSE: BMY) buyout offer in ...
Bristol-Myers Squibb Lung Cancer Drug Looks Promising in Clinical Trial
Pharmaceutical giant Bristol-Myers Squibb is developing a new drug that may be uniquely effective against lung cancer, among other diseases.
Bristol-Myers Tests Sprycel in Lung Cancer in New Study  Bloomberg
BMS launches global academic collaboration in immuno-oncology  PMLiVE
Sale of ex-Bristol-Myers plant complete
... the site of a pharmaceutical manufacturing operation for five decades, beginning with the Foster-Milburn Co. first opened the Forest Avenue plant in 1962.
FDA approves 7 companies to sell generic Plavix in pharmacies immediately
Brand-name Plavix is marketed jointly by Bristol-Myers Squibb Co. and Sanofi SA. They're now offering coupons giving a big discount off the brand price, which is currently about $200 per month.
Bristol-Myers, Sanofi blockbuster drug Plavix topples over patent cliff  MedCity News
FDA OKs multiple companies to sell generic Plavix  BusinessWeek
Plavix Set to Lose Patent Protection
Faced with an expected influx of cheaper generic alternatives, Bristol-Myers Squibb, which sells Plavix in the United States under a partnership with Sanofi-Aventis, has said it no longer plans to actively promote the drug.
After a Sentence to Write Sentences, Dr. Bodnar Ends a Legal Chapter  Wall Street Journal
Ex-BMS exec finishes book, and sentence, in conviction  FiercePharma
Targeted Cancer Drugs With Punch: The Next Big Class of Antibodies
... venture-backed companies that are seeking to come up with new antibody-drug conjugates, or provide new enabling technologies, I thought it would useful to put together a list of companies seeking to play a role.